See the DrugPatentWatch profile for ruxolitinib

The generic version of ruxolitinib was approved by the United States Food and Drug Administration (FDA) on November 16, 2020. The approval was announced in a press release by the FDA, which stated that the agency had approved the first generic version of ruxolitinib tablets for the treatment of certain blood disorders. Ruxolitinib is a medication that is used to treat myelofibrosis and polycythemia vera, two rare blood disorders.

According to DrugPatentWatch.com, ruxolitinib was originally approved by the FDA in 2011 and is marketed under the brand name Jakafi by Incyte Corporation. The patent for Jakafi is set to expire in 2027, but the FDA's approval of a generic version of the drug means that other manufacturers will be able to produce and sell generic ruxolitinib starting in 2020.

The approval of a generic version of ruxolitinib is expected to increase access to the medication and potentially lower its cost for patients. Generic drugs are typically less expensive than brand-name drugs because they do not have to go through the same expensive clinical trials as brand-name drugs.

In summary, the generic version of ruxolitinib was approved by the FDA on November 16, 2020. This approval is expected to increase access to the medication and potentially lower its cost for patients.

Sources:

1. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-version-jakafi-treat-certain-blood-disorders>
2. <https://www.drugpatentwatch.com/patent/INSM-38713>